Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

52.99 -0.72 (-1.34%)
Streaming Delayed Price Updated: 2:06 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports Fourth Quarter and Full Year 2025 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
From Tempus AI, Inc.
Via Business Wire
News headline image
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes
From Ambry Genetics
Via Business Wire
News headline image
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield
From Ambry Genetics
Via Business Wire
News headline image
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces the Launch of Paige Predict
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology
From Tempus
Via Business Wire
News headline image
Northwestern Medicine Selects Tempus to Expand Genomic Testing
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports Third Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Participate in the Stifel 2025 Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Report Third Quarter 2025 Financial Results on November 4
From Tempus AI, Inc.
Via Business Wire
News headline image
Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity
From Ambry Genetics
Via Business Wire
News headline image
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
From Tempus AI, Inc.
Via Business Wire
News headline image
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
From Ambry Genetics
Via Business Wire
News headline image
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
From Tempus AI, Inc.
Via Business Wire
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.